NuVasive sets IPO (initial public offering) for up to $97 million
This article was originally published in Clinica
NuVasive, a spinal technology developer whose financial backers include Johnson & Johnson Development Corporation and William Blair Capital Partners, has set $97.1m as the new upper limit for its impending initial public offering on Nasdaq. In March the company filed a registration statement with the SEC for a maximum upper limit of $92m (see Clinica No 1099, p 16).
You may also be interested in...
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
HBW Market News: FTC Ends Another Supplement Scam, Australia Win For ChromaDex, GOED Report, Herbalife
Herbalife opens 9,200 square-foot training facility in China; GOED's latest annual market report, covering 2017-2018, is available; ChromaDex has two-tear exclusivity for nicotinamide riboside chloride in Australia; and A.S. Research arthritis claims for Synovia end in FTC settlement.
Pharma sells the rights to Germany’s Cheplapharm, which obtained EU/Russia rights in October. Cerecor will acquire Aevi Genomics for $16.1m plus contingent value rights.